IDEV - ETF AI Analysis

Top Page

iShares Core MSCI International Developed Markets ETF (IDEV)

Rating:66Neutral

Price Target:―

IDEV’s rating reflects a solid, diversified mix of high-quality international companies, led by strong contributors like Novartis, AstraZeneca, HSBC, and Toyota, which all show robust financial health, positive earnings commentary, and generally supportive valuations or technical trends. Stability from holdings such as Nestlé and Royal Bank of Canada further supports the fund, while some names like Shell and Siemens introduce moderate risk through mixed technical signals, growth challenges, or cash flow efficiency issues, highlighting that not all positions are equally strong. Overall, the main risk is that performance is still partly tied to a few sectors and companies facing valuation or short-term momentum concerns, even within a broadly diversified developed-markets portfolio.

Positive Factors

Low Expense Ratio

The fund charges a very low fee, which helps investors keep more of their returns over time.

Broad International Diversification

Holdings spread across many developed countries like Japan, the UK, Europe, Canada, and others help reduce the impact of problems in any single market.

Healthy Size and Recent Performance

The ETF has a large asset base and has shown steady gains over the past month, three months, and year-to-date, suggesting it is widely used and has been performing reasonably well.

Negative Factors

Heavy Tilt to Financials and Industrials

A large share of the portfolio is in financial and industrial companies, which can hurt returns if these sectors struggle.

Mixed Results Among Top Holdings

While some leading positions like ASML, Roche, Siemens, Toyota, and others have been strong, several other major holdings have been weak, which can drag on overall performance.

Limited Exposure to High-Growth Tech

Technology makes up a relatively small part of the portfolio, so the fund may benefit less if global tech stocks outperform.

IDEV vs. SPDR S&P 500 ETF (SPY)

AUM28.18B

RegionDeveloped Markets

Expense Ratio0.04%

Beta0.74

IssueriShares

Inception DateMar 21, 2017

Dividend Yield3.3%

Asset ClassEquity

Index TrackedMSCI World ex USA IMI

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,605,112

30 Day Avg. Volume2,602,899

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

96.63

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering2238

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IDEV Summary

IDEV is an ETF that tracks the MSCI World ex USA IMI index, giving you broad exposure to stocks in developed countries outside the U.S. and Canada. It owns thousands of companies across many sectors and regions, including well-known names like Nestlé, Toyota, and ASML. Someone might invest in IDEV to diversify beyond the U.S. market and tap into long-term growth in Europe, Japan, and other developed economies, all in a single fund. A key risk is that international stock prices can go up and down with global markets and currency swings.

How much will it cost me?The iShares Core MSCI International Developed Markets ETF (IDEV) has an expense ratio of 0.04%, meaning you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically costs less to operate compared to actively managed funds.

What would affect this ETF?Positive drivers for IDEV could include economic growth in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare, which are heavily represented in the ETF. However, negative factors such as rising interest rates or geopolitical tensions in Europe and Asia could impact the performance of key holdings like ASML, Nestlé, and HSBC, as well as broader sector trends like energy and industrials. Regulatory changes or currency fluctuations in these regions may also affect returns.

IDEV Top 10 Holdings

IDEV’s story right now is being written by a handful of global heavyweights. ASML is the clear engine, with its rising share price giving the fund a lift as chip demand stays strong. A trio of European pharma giants—Roche, AstraZeneca, and Novartis—are also climbing steadily, adding a defensive but growing backbone. On the financial side, HSBC and Mitsubishi UFJ are rising, while Royal Bank of Canada is more steady than exciting. Overall, the ETF leans toward international financials and health care, with broad exposure across Europe and Japan and no single stock dominating.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	1.83%	$509.09M	€453.03B	72.70%	76 Outperform
ROG	Roche Holding AG	1.11%	$310.38M	CHF281.05B	26.73%	73 Outperform
AZN	AstraZeneca	1.09%	$303.76M	$306.87B	20.11%	80 Outperform
NOVN	Novartis AG	1.08%	$302.08M	CHF237.56B	22.14%	80 Outperform
HSBA	HSBC Holdings	1.03%	$286.33M	£219.64B	42.06%	80 Outperform
NESN	Nestlé SA	0.95%	$265.49M	CHF202.69B	0.58%	71 Outperform
SHEL	Shell (UK)	0.87%	$243.38M	£175.14B	22.65%	73 Outperform
RY	Royal Bank Of Canada	0.82%	$228.14M	$231.31B	42.10%	75 Outperform
SAP	SAP SE	0.76%	$210.84M	€194.68B	-32.79%	66 Neutral
7203	Toyota Motor	0.74%	$206.46M	¥45.37T	23.81%	80 Outperform

IDEV Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

86.61

Negative

100DMA

83.21

Positive

200DMA

79.41

Positive

Market Momentum

MACD

0.03

Positive

RSI

36.35

Neutral

STOCH

26.48

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDEV, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 88.95, equal to the 50-day MA of 86.61, and equal to the 200-day MA of 79.41, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 36.35 is Neutral, neither overbought nor oversold. The STOCH value of 26.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDEV.

IDEV Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IDEV	―	―	$28.18B	0.04%	66 Neutral
VEA	―	―	$212.27B	0.03%	60 Neutral
SCHF	―	―	$59.05B	0.03%	63 Neutral
SPDW	―	―	$36.68B	0.03%	62 Neutral
DFAI	―	―	$14.95B	0.18%	64 Neutral
AVDE	―	―	$14.43B	0.23%	65 Neutral

Performance Comparison

IDEV

iShares Core MSCI International Developed Markets ETF

85.00

18.22

27.28%

VEA

Vanguard FTSE Developed Markets ETF

―

SCHF

Schwab International Equity ETF

―

SPDW

SPDR Portfolio Developed World ex-US ETF

―

DFAI

Dimensional International Core Equity Market ETF

―

AVDE

Avantis International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents